ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Dana-Farber Picks Rosenthal To Direct New Center For Integrated Therapies.

June 23, 2000

Reauthorization Bill Ready For Senate Floor; Report to Panel Makes Clear Why Renewal Needed

April 22, 1988

Intramural Funding To Decrease, R01s Increase, Klausner Says

September 15, 1995

ImClone Offered C225 Deal To Seven Firms Prior To BMS

February 22, 2002

Agriculture Dept. Asks clearinghouse To Consider Broader Risk Assessment Data

July 14, 1978

ASCO, AACR Nursing Society Programs Set

May 6, 1977